Analysts See $-1.94 EPS for BeiGene, Ltd. (BGNE); Oracle (ORCL) Had 27 Bullish Analysts

April 17, 2018 - By Peter Erickson

BeiGene, Ltd. (NASDAQ:BGNE) Logo

Among 42 analysts covering Oracle (NYSE:ORCL), 27 have Buy rating, 0 Sell and 15 Hold. Therefore 64% are positive. Oracle had 115 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 16 by UBS. The stock has “Buy” rating by Jefferies on Tuesday, October 17. The firm earned “Buy” rating on Friday, August 25 by RBC Capital Markets. The rating was maintained by Barclays Capital on Monday, March 12 with “Overweight”. BMO Capital Markets initiated the shares of ORCL in report on Friday, January 8 with “Market Perform” rating. The stock has “Buy” rating by Piper Jaffray on Wednesday, October 4. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, March 20 report. The rating was downgraded by KeyBanc Capital Markets on Tuesday, March 20 to “Sector Weight”. Piper Jaffray maintained Oracle Corporation (NYSE:ORCL) on Thursday, February 15 with “Buy” rating. The firm earned “Buy” rating on Sunday, September 10 by Stifel Nicolaus. See Oracle Corporation (NYSE:ORCL) latest ratings:

11/04/2018 Broker: Monness Crespi & Hardt Rating: Neutral Initiates Coverage On
20/03/2018 Broker: MUFG Securities Americas Inc Rating: Buy New Target: $58.0
20/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $55 New Target: $53 Maintain
20/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $62 New Target: $60 Maintain
20/03/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
20/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Downgrade
20/03/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Sector Weight Downgrade
15/03/2018 Broker: Cleveland Rating: Hold
15/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $55.0 Maintain
12/03/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $56 New Target: $60 Maintain

Analysts expect BeiGene, Ltd. (NASDAQ:BGNE) to report $-1.94 EPS on May, 9.They anticipate $0.67 EPS change or 52.76% from last quarter’s $-1.27 EPS. After having $-2.19 EPS previously, BeiGene, Ltd.’s analysts see -11.42% EPS growth. The stock decreased 0.26% or $0.44 during the last trading session, reaching $166.18. About 121,484 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 354.57% since April 17, 2017 and is uptrending. It has outperformed by 343.02% the S&P500.

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports application, platform, and infrastructure technologies for information technology environments worldwide. The company has market cap of $190.52 billion. It provides services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service. It has a 54.58 P/E ratio. The firm licenses its Oracle Database software, which enables storage, retrieval, and manipulation of data; and Oracle Fusion Middleware software to build, deploy, secure, access, and integrate business applications, as well as automate their business processes.

The stock increased 1.35% or $0.62 during the last trading session, reaching $46.67. About 5.50 million shares traded. Oracle Corporation (NYSE:ORCL) has risen 1.20% since April 17, 2017 and is uptrending. It has underperformed by 10.35% the S&P500.

Investors sentiment increased to 1.15 in 2017 Q4. Its up 0.02, from 1.13 in 2017Q3. It improved, as 80 investors sold Oracle Corporation shares while 488 reduced holdings. 126 funds opened positions while 526 raised stakes. 2.29 billion shares or 1.37% less from 2.32 billion shares in 2017Q3 were reported. Bowling Port Management Limited Co accumulated 15,099 shares or 0.09% of the stock. Symphony Asset Management Ltd Liability Corporation holds 60,808 shares. Veritable Ltd Partnership invested 0.13% of its portfolio in Oracle Corporation (NYSE:ORCL). Agf Invests Incorporated reported 480,630 shares stake. Edgemoor Investment Advisors Inc has 11,187 shares. New York-based Bancorp Of Mellon Corporation has invested 0.58% in Oracle Corporation (NYSE:ORCL). Optimum Invest Advsr reported 31,130 shares or 0.47% of all its holdings. Klingenstein Fields & Limited Company holds 0.72% of its portfolio in Oracle Corporation (NYSE:ORCL) for 414,976 shares. Finemark Bankshares Tru holds 64,623 shares or 0.19% of its portfolio. Notis holds 1.09% or 40,212 shares in its portfolio. Stifel Corporation reported 2.23M shares. Iowa Savings Bank owns 37,108 shares. Cullen Frost Bankers holds 24,207 shares. Fairfield Bush & stated it has 3.02% of its portfolio in Oracle Corporation (NYSE:ORCL). Harvey Cap Inc has 3.35% invested in Oracle Corporation (NYSE:ORCL) for 195,334 shares.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $8.84 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

Oracle Corporation (NYSE:ORCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: